|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13-14
|
|
pubmed:dateCreated |
2005-8-10
|
|
pubmed:abstractText |
The most common opportunistic viral pathogen after lung transplantation is cytomegalovirus (CMV). Oral valganciclovir, a prodrug of ganciclovir, has been introduced as a potential drug for prophylaxis and treatment of CMV infection and disease in lung transplantation. The goal of this study was to describe our initial experience with oral valganciclovir for pre-emptive treatment of CMV infections after lung transplantation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0043-5325
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
117
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
480-4
|
|
pubmed:meshHeading |
pubmed-meshheading:16091875-Administration, Oral,
pubmed-meshheading:16091875-Adult,
pubmed-meshheading:16091875-Antiviral Agents,
pubmed-meshheading:16091875-Cytomegalovirus,
pubmed-meshheading:16091875-Cytomegalovirus Infections,
pubmed-meshheading:16091875-Female,
pubmed-meshheading:16091875-Ganciclovir,
pubmed-meshheading:16091875-Humans,
pubmed-meshheading:16091875-Lung Transplantation,
pubmed-meshheading:16091875-Male,
pubmed-meshheading:16091875-Middle Aged,
pubmed-meshheading:16091875-Opportunistic Infections,
pubmed-meshheading:16091875-Pilot Projects,
pubmed-meshheading:16091875-Postoperative Care,
pubmed-meshheading:16091875-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
|
|
pubmed:affiliation |
Department of Cardiothoracic Surgery, Vienna General Hospital, Vienna Medical University, Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
